First Tracks Biotherapeutics reported positive early clinical data for its CD122 antibody ANB033 in a placebo-controlled Phase I study in celiac disease. The company said the program met primary and key secondary endpoints, strengthening the rationale for targeting CD122 in a condition where gluten exposure drives immune-mediated intestinal damage. The update places CD122 inhibition into a broader competitive set of celiac approaches, but the available details emphasize that the data are still early and do not establish superiority over other investigational therapies. Nonetheless, achieving endpoints in Phase I signals that immune modulation is reaching the intended biology. For investors and R&D teams, the practical takeaway is dosing and tolerability: CD122-directed strategies must prove they can deliver durable intestinal protection while managing safety in chronic disease settings.